Key terms
About ABBV
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest ABBV news
Mar 26
8:24pm ET
AbbVie price target raised to $195 from $185 at Barclays
Mar 25
9:10pm ET
Analysts Offer Insights on Healthcare Companies: Fate Therapeutics (FATE) and AbbVie (ABBV)
Mar 25
2:44pm ET
Fly Insider: NextNav, Akamai among week’s notable insider trades
Mar 25
8:35am ET
AbbVie to acquire Landos Biopharma for $20.42 per share in cash plus CVR
Mar 25
8:34am ET
AbbVie to acquire Landos Biopharma got $20.42 per share in cash
Mar 25
8:32am ET
AbbVie to acquire Landos Biopharma for $20.42 per share in cash
Mar 24
5:04am ET
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV) and Legend Biotech (LEGN)
Mar 24
5:03am ET
Analysts Have Conflicting Sentiments on These Healthcare Companies: AbbVie (ABBV) and Gilead Sciences (GILD)
Mar 22
3:06pm ET
AbbVie confirms FDA grants full approval for Elahere for certain ovarian cancers
Mar 22
2:34pm ET
FDA approves mirvetuximab soravtansine-gynx for certain cancers
Mar 22
6:42am ET
AbbVie price target raised to $190 from $188 at Guggenheim
Mar 15
12:03pm ET
JPMorgan biotech/pharma analysts hold an analyst/industry conference call
Mar 12
8:40am ET
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Incyte (INCY), AbbVie (ABBV) and ACADIA Pharmaceuticals (ACAD)
Mar 05
8:08am ET
Allergan Aesthetics announces FDA approval of JUVEDERM VOLUMA XC
Mar 05
7:16am ET
AbbVie makes milestone payment to Dragonfly after dosing in solid tumor trial
Feb 28
6:06am ET
AbbVie, OSE Immunotherapeutics enter pact to develop OSE-230
Feb 27
4:08pm ET
Regenxbio expects cash to fund operations into 2H25
Feb 27
7:49am ET
AbbVie’s epcoritamab granted priority review by FDA in follicular lymphoma
Feb 27
7:48am ET
Genmab, AbbVie announce FDA priority review for sBLA
Feb 26
11:45am ET
Truist biotech analysts hold an analyst/industry conference call
Feb 26
4:55am ET
Truist biotech analysts hold an analyst/industry conference call
Feb 22
8:06am ET
AbbVie, Tentarix announce multi-year collaboration
Feb 21
5:39pm ET
AbbVie targeting bond offering of at least $13B for M&A, Bloomberg says
Feb 21
12:10pm ET
Truist biotech analysts hold an analyst/industry conference call
Feb 20
9:12am ET
AbbVie Announces New CEO and Regulatory Disclosure Updates
Feb 20
9:02am ET
AbbVie CEO Richard Gonzalez to retire, Robert Michael to succeed
Feb 20
8:45am ET
Largest borrow rate increases among liquid names
Feb 12
12:29pm ET
AbbVie price target raised to $172 from $167 at BofA
Feb 12
10:20am ET
AbbVie (NYSE:ABBV) Closes ImmunoGen Deal, Lowers Q1 Forecast
Feb 12
8:21am ET
AbbVie Completes ImmunoGen Acquisition Amidst Cautious Outlook
Feb 12
7:42am ET
AbbVie backs FY24 adjusted EPS view $11.05-$11.25, consensus $11.18
Mar 17
8:15am ET
2 Top Dividend Stocks to Buy Hand Over Fist
Mar 13
8:24am ET
How Much a $1 Million Portfolio Would Pay in Dividends
Mar 11
9:28am ET
3 Pharmaceutical Stocks to Buy Hand Over Fist in March
Mar 09
9:00am ET
The AI Race Gets Litigious
Mar 09
2:59am ET
Have $2,500? 2 Superior Growth Stocks to Buy in 2024
No recent press releases are available for ABBV
ABBV Financials
Key terms
Ad Feedback
ABBV Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
ABBV Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range